Six-Gene clue: could a simple test forecast lung spread in breast cancer?

NCT ID NCT07752966

Not yet recruiting Knowledge-focused Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study is testing whether a six-gene risk score, calculated from a tumor tissue sample, can predict which women with early-stage breast cancer are more likely to develop lung metastasis. Researchers will follow 330 women aged 18 to 70 for up to 120 months, tracking lung metastasis and survival. The goal is to see if this genetic test adds value beyond standard clinical factors like tumor stage and subtype, potentially helping tailor future monitoring and treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A six-gene risk score test on tumor tissue
What this could lead to: If successful, this could give doctors a new tool to identify breast cancer patients at higher risk of lung metastasis, potentially guiding more personalized follow-up and treatment decisions.
What could go wrong: This is an observational study, so it cannot prove the test changes outcomes. The risk score may not perform better than existing clinical indicators, and results may not apply to all breast cancer subtypes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER LUNG METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER LUNG METASTASIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.